GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (OSTO:CAMX) » Definitions » Notes Receivable

Camurus AB (OSTO:CAMX) Notes Receivable : kr0 Mil (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Camurus AB Notes Receivable?

Camurus AB's Notes Receivable for the quarter that ended in Dec. 2024 was kr0 Mil.


Camurus AB Notes Receivable Historical Data

The historical data trend for Camurus AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB Notes Receivable Chart

Camurus AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Camurus AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Camurus AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Camurus AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Camurus AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Camurus AB Business Description

Traded in Other Exchanges
Address
Ideon Science Park, Lund, SWE, SE-223 70
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.

Camurus AB Headlines